Melatonin in Heart Failure: A Promising Therapeutic Strategy?

被引:40
|
作者
Nduhirabandi, Frederic [1 ]
Maarman, Gerald J. [1 ]
机构
[1] Univ Cape Town, Fac Hlth Sci, Dept Med, Cardioprotect Grp,HICRA, ZA-7935 Cape Town, South Africa
来源
MOLECULES | 2018年 / 23卷 / 07期
基金
欧洲研究理事会; 新加坡国家研究基金会;
关键词
cardiac remodeling; cardioprotection; cardiomyopathy; fibrosis; heart failure; hypertension; ischemic heart disease; melatonin; metabolic syndrome; ISCHEMIA-REPERFUSION INJURY; NOCTURNAL BLOOD-PRESSURE; PULMONARY-HYPERTENSION; MYOCARDIAL-INFARCTION; METABOLIC SYNDROME; EJECTION FRACTION; RISK-FACTORS; PROTECTS; RATS; ASSOCIATION;
D O I
10.3390/molecules23071819
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heart failure is a multifactorial clinical syndrome characterized by the inability of the heart to pump sufficient blood to the body. Despite recent advances in medical management, poor outcomes in patients with heart failure remain very high. This highlights a need for novel paradigms for effective, preventive and curative strategies. Substantial evidence supports the importance of endogenous melatonin in cardiovascular health and the benefits of melatonin supplementation in various cardiac pathologies and cardiometabolic disorders. Melatonin plays a crucial role in major pathological processes associated with heart failure including ischemic injury, oxidative stress, apoptosis, and cardiac remodeling. In this review, available evidence for the role of melatonin in heart failure is discussed. Current challenges and possible limitations of using melatonin in heart failure are also addressed. While few clinical studies have investigated the role of melatonin in the context of heart failure, current findings from experimental studies support the potential use of melatonin as preventive and adjunctive curative therapy in heart failure.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
    Khan, M. A.
    Deaton, C.
    Rutter, M. K.
    Neyses, L.
    Mamas, M. A.
    HEART FAILURE REVIEWS, 2013, 18 (02) : 141 - 148
  • [22] New approaches in the treatment of heart failure: A change in therapeutic strategy
    Rebollar, Juan Carlos Obaya
    ATENCION PRIMARIA, 2022, 54 (05):
  • [23] A novel therapeutic strategy for acute decompensated heart failure with vasodilators
    Pan, Yu
    Yang, Juan
    Feng, Zhu Qing
    Yuan, Yan
    Tang, Xue Yin
    Dong, Jiang Chuan
    MEDICAL HYPOTHESES, 2024, 184
  • [24] Cell therapy for heart failure: the need for a new therapeutic strategy
    Povsic, Thomas J.
    O'Connor, Christopher M.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (08) : 1107 - 1126
  • [25] DNA methylation inhibition: A novel therapeutic strategy for heart failure
    Kao, Yu-Hsun
    Lien, Gi-Shih
    Chao, Tze-Fan
    Chen, Yi-Jen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 176 (01) : 232 - 233
  • [26] Baroreflex activation as a novel therapeutic strategy for diastolic heart failure
    Mathias C. Brandt
    Navid Madershahian
    Ralf Velden
    Uta C. Hoppe
    Clinical Research in Cardiology, 2011, 100 : 249 - 251
  • [27] Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
    M. A. Khan
    C. Deaton
    M. K. Rutter
    L. Neyses
    M. A. Mamas
    Heart Failure Reviews, 2013, 18 : 141 - 148
  • [28] Baroreflex activation as a novel therapeutic strategy for diastolic heart failure
    Brandt, Mathias C.
    Madershahian, Navid
    Velden, Ralf
    Hoppe, Uta C.
    CLINICAL RESEARCH IN CARDIOLOGY, 2011, 100 (03) : 249 - 251
  • [29] Adenovirus gene transfer of SERCA in heart failure. A promising therapeutic approach
    Baartscheer, A
    CARDIOVASCULAR RESEARCH, 2001, 49 (02) : 249 - 252
  • [30] Subcutaneous BNP administration in symptomatic human heart failure: A novel therapeutic strategy for congestive heart failure
    Chen, HH
    Nordstrom, LJ
    Redfield, MM
    Burnett, JC
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 240A - 240A